Cosmic Drugs And Chemical Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
- Paid Up Capital ₹ 5.41 M
- Company Age 34 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
- Revenue Growth -44.76%
- Profit Growth 41.35%
- Ebitda 48.31%
- Net Worth -7.10%
- Total Assets -6.82%
About Cosmic Drugs And Chemical
Cosmic Drugs And Chemical Private Limited (CDACPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 April 1990 and has a history of 34 years and ten months. Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 5.41 M.
The company currently has active open charges totaling ₹2.50 M.
Pareshbhai Balwantray and Artiben Joshi serve as directors at the Company.
Company Details
-
Location
Vadodara, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ1990PTC013640
-
Company No.
013640
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Apr 1990
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Cosmic Drugs And Chemical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pareshbhai Balwantray
|
Managing Director | 18-Apr-1990 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Artiben Joshi
|
Director | 21-Feb-2005 | Current |
Financial Performance of Cosmic Drugs And Chemical.
Cosmic Drugs And Chemical Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 44.76% decrease. The company also saw a substantial improvement in profitability, with a 41.35% increase in profit. The company's net worth dipped by a decrease of 7.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cosmic Drugs And Chemical?
In 2017, Cosmic Drugs And Chemical had a promoter holding of 71.87% and a public holding of 28.13%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- Union Bank Of India : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jul 1992 | Union Bank Of India | ₹2.50 M | Open |
How Many Employees Work at Cosmic Drugs And Chemical?
Unlock and access historical data on people associated with Cosmic Drugs And Chemical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cosmic Drugs And Chemical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cosmic Drugs And Chemical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
